The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co. in Glycemic Control of Diabetic Patients
The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co. in Glycemic Control of Diabetic Patients
Background: Metformin is usually using for glycemic control in type 2 diabetes mellitus.
 Different pharmaceutical types of metformin are available. As a clinical trial, we compared
 the efficacy and complications of metformin produced by "Pars Mino pharmaceutical company,
 Iran" with "Apotex pharmaceutical company, Canada", in type 2 diabetic patients.

 Method: 18 eligible women with type 2 diabetes were given metformin "Pars Mino" or "Apotex"
 (500 mg twice a day) each for 6 weeks period in a randomized, double blind, crossover study.
 After 2 weeks washout period another 6 weeks period with another Brand of metformin was
 prescribed. FBS, HbA1C, lipid profile (Cholesterol, TG, HDL, and LDL), weight, and BMI were
 assessed before and after each treatment phase. The results were compared with each other by
 paired sample T-test, Independent sample T-test.
Inclusion Criteria:

 -  Mild hyperglycemia, no contraindication for metformin, poor controlled diabetes

 Exclusion Criteria:

 -  Creatinine more than 1.5, severe organ damage